Wife discovers husband secretly spent S$80k on in-game purchases, plunging family into debt
In a post on the r/singaporefi forum, the woman shared that her husband, who works in a tech/data role at a bank, had been spending thousands of dollars each month on online games. The spending spree went unnoticed for several months until the debts spiralled out of control.
She added that her husband has since acknowledged the problem and is now receiving counselling. The couple is also trying to work out a way forward, and he has expressed commitment to repaying the debt through a structured plan.
They are currently deciding between enrolling in a Debt Management Programme (DMP) through Credit Counselling Singapore or taking up a Debt Consolidation Plan (DCP) with a bank, but are unsure about the implications of either option.
'Our main concern is how this might affect his credit score, future loan eligibility, and especially his career,' she wrote. 'He's in the finance sector, and we're worried how either route might impact his job prospects within the industry.'
She ended the post by reaching out to others who may have faced similar situations: 'Which option is less damaging to credit score and future loan eligibility? Has anyone gone through either programme and can share your loan amount and monthly payment + tenure? I'm aware of how crappy this whole situation is but I am willing to support him to see our family through this. Any kind advice would be appreciated. thank you.' 'Tough one, kudos to you for accompanying him through it.'
In the comments, many were shocked that her husband had managed to spend such a large sum on in-game purchases, with some calling the figure 'crazy' and 'unbelievable.'
One Redditor shared their own experience, saying, 'I dunno what to say. Once, I spent S$80 on multiple skins for ML; that's the most I spent. It felt horrible. Paying for something so meaningless. Your husband needs to have a clear sense of perspective. You also need to help him change his focus from games to you. It will help you both significantly.' See also Simple Tips to Stop Fights in Relationships
Another said, 'S$80k for games is wild. I've played games (console and offline only) for the past 30 years. I reckon my total spending, including all hardware and games, will be a fraction of that…'
A third commented, 'I could not even get S$1,000 for games, let alone $80,000.'
Some users also suggested that, alongside repaying the debt, the husband should also seek help for potential gaming addiction, warning that without proper intervention, the issue could resurface.
Amid the criticism, others commended the woman for choosing to stand by her husband in times of crisis.
One commented, 'Tough one, kudos to you for accompanying him through it.'
Another stated, 'Just want to say, good on you… for sticking through this with him when it's easier to give it up.'
In other news, a nursing student recently took to Reddit to express her frustration over the negative perceptions people have of her chosen career.
In her post titled 'Why are nurses so poorly regarded in society despite how hard they work?', the student shared that whenever she tells someone she is studying nursing in a polytechnic, she often receives a 'judgy look.' Some even go so far as to ask whether nursing was her 'first choice.'
Read also: 'Why is nursing looked down on?' Student in Singapore pushes back against tired stereotypes
Featured image by freepik (for illustration purposes only)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNA
25 minutes ago
- CNA
Commentary: China is playing the long game on trade. It's working
SINGAPORE: President Donald Trump's trade war was meant to rebalance global power in America's favour. Instead, China is playing the long game, enduring short-term economic pain to shape any eventual deal to its advantage. The strategy appears to be working – for now. On Monday (Aug 11), Washington granted Beijing another 90-day reprieve, extending a pause on tariffs through Nov 10. China announced it would do the same. Markets welcomed the move, which offered some relief after months of tension. The delay will give President Xi Jinping's policymakers more time to plan their next move. Time is Xi's ally. So far, the clearest outcome of each round of talks has been a commitment to meet again. Despite Trump's insistence that China has taken significant steps to improve their trade relationship, Beijing has made no consequential concessions on any of his key concerns. (China has offered some small compromises, none on the scale of American demands.) The extension has come at a delicate time for the economy, which is plagued by sluggish domestic demand and a slowdown in the property sector. Bloomberg Economics says that China is among the few major nations without a clear timeline or terms for a deal, while others have struck agreements to secure lower tariffs. Even with this reprieve, it notes, Beijing faces average US tariffs of 40 per cent – almost 25 percentage points above the global average. This will hurt prospects for Chinese citizens, who have enjoyed more than three decades of near double-digit growth. The economy expanded by 5.2 per cent in April-June from a year earlier – enviable by global standards – but anxieties among the once-thriving middle class over the future for their children are rising. Youth unemployment remains stubbornly high, with joblessness at 14.5 per cent in June. That figure has improved in recent months, but analysts point to significant challenges: More than 12 million university students are set to graduate with hopes of joining the workforce. A LONG BATTLE Still, China is betting that despite these economic costs, it can fight this trade war to the end. Politically, Beijing is preparing the population for a long battle. State media editorials in recent months have lauded a Mao-era philosophy as a possible strategy to counter American pressure. They reference the former Chinese leader's 1938 essay On Protracted War, which laid out his approach to combating the invading Japanese between 1937 and 1945. During a series of lectures in May and June 1938, Mao spoke of how the 'contest of strength is not only a contest of military and economic power, but also a contest of human power and morale'. Scholars say the idea was to alert his fellow citizens that the war would be long and gruelling, but could be won through endurance and unity. Despite millions of Chinese dead, Mao refused to yield. The conflict only ended after Japan surrendered in World War II in 1945. (Mao's civil war with the Nationalists lasted another four years.) Xi appears to be heeding his predecessor's counsel: patience, at all costs – with the aim of shifting the odds in Beijing's favour. CHINA'S STRATEGY OF SELF-RELIANCE Domestically, Xi has the levers of the Chinese state at his disposal to help him craft a now well-worn narrative that the West is keeping China down. The trade war has fuelled those views, which play well with an already disgruntled citizenry. Internationally, Trump is doing much of the work for him. In contrast to Washington's chaos on everything from trade to international students' university admissions, Beijing is presenting itself as a champion of multilateralism – notwithstanding that it's also trying to reshape the world order to its advantage. China is happy to keep the talks going, but is unlikely to make any concessions, as William Yang, the International Crisis Group's senior North East Asia analyst, says in a note. 'China believes momentum is on its side because Trump has a stronger desire to sign a deal with Beijing so that he can claim victory and secure a summit with Xi in the fall.' But Washington's economic leverage is gradually eroding, as China pushes ahead with its strategy of self-reliance. Beijing wants to reduce dependence on US markets, and deepen control over critical supply chains, as a report from the RAND thinktank notes. China on Monday urged local firms to avoid using Nvidia's H20 processors, especially in government projects, following a White House directive requiring it and AMD to pay 15 per cent of Chinese AI chip sales to Washington.
Straits Times
3 hours ago
- Straits Times
Cancer biotech firm Hummingbird Bioscience to target inflammatory diseases with precision drugs
Sign up now: Get ST's newsletters delivered to your inbox Hummingbird Bioscience recently received an award from the World Intellectual Property Organisation, the UN agency dedicated to innovation and creativity. SINGAPORE – Singapore-headquartered biotech firm Hummingbird Bioscience, known for developing antibodies for cancer, is turning its sights to drugs for immunology and inflammatory diseases, such as lupus and inflammatory bowel disease. It will be adapting antibody-drug conjugates which it developed for cancer treatment to target these diseases. It is now about 12 months to 18 months away from filing regulatory approvals in Asia, Europe and the US to start clinical trials for an undisclosed number of these drugs. These consist of antibodies that have the missile-like ability to seek out specific targets, along with a payload, which is a drug intended to treat a disease. Hummingbird recently received an award from the World Intellectual Property Organisation (Wipo), the United Nations agency dedicated to innovation and creativity. At the 2025 Wipo Global Awards held at the organisation's headquarters in Geneva on July 11, it was among 10 small and medium -sized enterprises worldwide that were celebrated for commercialising their intellectual property (IP). 'Hummingbird Bioscience exemplifies how innovative companies can thrive with a well-crafted IP strategy. The company has built a robust IP plan with a strong patents portfolio and a successful licensing-based business model,' said Mr Fu Zhikang, director of IP strategy solutions at Ipos International, a subsidiary of the Intellectual Property Office of Singapore. The biotech firm is looking to expand its pipeline of products. Its chief scientific officer and co-founder Jerome Boyd-Kirkup told The Straits Times: 'Our mission has been to build the next generation of potentially transformative therapies for patients with cancer and autoimmune diseases. 'A large part of that is to have a strong IP portfolio which can underpin that development and ensure that the innovations that are done here in Singapore can be translated globally.' The company's focus for the future will be on immunology and inflammation, said Dr Boyd-Kirkup. These diseases are a group of chronic conditions characterised by a dysregulated immune system leading to inflammation and tissue damage. It is generally believed that up to 10 per cent of the world's population is affected by these conditions, though estimates vary. The therapeutics for immunology and inflammatory diseases have seen keen interest from biopharma companies worldwide – the global market size for this area is projected to grow from US$103 billion (S$132.4 billion) in 2024 to US$257 billion by 2032. In the context of immunology and inflammatory diseases, the target for Hummingbird's antibody-drug conjugates may be immune cells that have become overactive or destructive, and a drug is selected to block the harmful response. Dr Boyd-Kirkup said that current treatments for immunology and inflammatory diseases are usually small molecule drugs such as corticosteroids and non-steroidal anti-inflammatory drugs. But the drawbacks of these drugs include concerns around side effects from long-term usage, and a short half-life, which means a drug needs to be taken more often as it does not stay long in the body. These two factors limit the efficacy and long-term treatment that is necessary for the treatment of many of such diseases. 'Antibody-drug conjugates offer a promising solution by enabling the targeted delivery of small molecule drugs, including immunosuppressives, directly to immune cells, thereby improving safety profiles and optimising exposure duration,' said Dr Boyd-Kirkup. The company, which has leveraged artificial intelligence (AI) in its discovery and development cycle for cancer drugs, will also be doing the same for immunology and inflammatory drugs. Immunology and inflammatory diseases are complex and involve many different cell types. In many cases, the places where the damage is occurring are not linked to the cells or processes happening in the area, said Dr Boyd-Kirkup. AI is being used to understand the biological processes involved in such diseases, he added. 'We have used AI to accelerate identification of key target cells and antigens involved in immunology and inflammatory diseases. The immunology and inflammatory antibody-drug conjugates we are working on are targeting key immune cell types involved in disease,' said Dr Boyd-Kirkup. He added that based on the clinical indications and antibody-drug conjugates that the company is looking into, there is a significant unmet clinical need. 'Clinical trials and commercialisation for therapies generally take around a decade. We are also open to the possibility of accelerating the process to the clinic through partnerships and licensing, which may bring in revenue for the company,' said Dr Boyd-Kirkup. In 2026, the company is also set to release results from its Phase 1B clinical trials for one of its key cancer drugs in development, HMBD-001. It is an antibody that targets the HER3 protein driving tumour growth and resistance against cancer drugs, currently being studied in a number of countries, including Singapore. Correction note: In an earlier version of the story, we referred to the company's chief scientific officer and co-founder as Mr Boyd-Kirkup. This is incorrect. His correct form of address is Dr Boyd-Kirkup.
CNA
7 hours ago
- CNA
Asia First - Wed 13 Aug 2025
02:27:30 Min From the opening bell across markets in Southeast Asia and China, to the biggest business interviews and top financial stories, tune in to Asia First to kick-start your business day.
